International mega-trends and growth prospects of the Finnish biotechnology industry: Recent economic research and policy implications

Journal of Commercial Biotechnology

Volumn 11, Issue 2, 2005, Pages 134-145

  Hermans, Raine ^a   Kulvik, Martti ^b   Ylä Anttila, Pekka ^a  

^a Elinkeinoelaman Tutkimuslaitos   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Capital structure; Input output analysis; Intangible assets; Price cost margins; Spatial agglomeration

Indexed keywords

DRUG PRODUCTS; ELECTRONICS INDUSTRY; FORECASTING; HEALTH CARE; INDUSTRIAL ECONOMICS; INDUSTRIAL MANAGEMENT; PUBLIC POLICY;

BIOTECHNOLOGY INDUSTRY; COST CRISIS; ECONOMIC GEOGRAPHY; INTELLECTUAL CAPITAL;

BIOTECHNOLOGY;

ALTEPLASE;

ARTICLE; BIOTECHNOLOGY; BLOOD CLOT LYSIS; COMPETITION; COST CONTROL; DRUG COST; DRUG INDUSTRY; ECONOMIC DEVELOPMENT; ELECTRONICS; FINANCIAL MANAGEMENT; FINLAND; FORECASTING; FORESTRY; GEOGRAPHY; GOVERNMENT REGULATION; HEALTH SERVICE; HUMAN; INTELLECT; INTERNATIONAL COOPERATION; MACHINE; POLICY; RESEARCH; STROKE;

EID: 14044267577     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3040111     Document Type: Article

References (28)

1. Hermans, R. (2004), 'International megatrends and growth prospects of the Finnish biotechnology industry - Essays on new economic geography, market structure of the pharmaceutical industry, sources of financing, intellectual capital and industry projections', Dissertation for the Department of Industrial Engineering and Management, Helsinki University of Technology, The Research Institute of the Finnish Economy, Helsinki.
2. Hermans, R. (2003), 'New Economic Geography of Market Potential - Innovation Intensity and Labor Structure in EU Regions', ETLA Discussion Paper No. 883, ETLA, Helsinki.
3. Hermans, R. and Linnosmaa, I. (2003), 'Price Markups and R&D Inputs: The Pharmaceutical Industry in Finland and the USA', ETLA Discussion Paper No. 877, ETLA, Helsinki.
4. Hermans, R. (2003), 'The capital and ownership structure of Finnish small and medium-sized bio-pharmaceutical companies', Dosis, Pharm. J., Vol. 19, (3), pp. 133-145 (in Finnish).
5. Hermans, R. (2004), 'Finance of Small Biopharmaceutical Industry in Finland Descriptive Analysis', ETLA Discussion Paper No. 888, ETLA, Helsinki.
6. Hermans, R. and Kauranen, I. (2003), 'Intellectual Capital and Anticipated Future Sales in Small and Medium-sized Biotechnology Companies', ETLA Discussion Paper No. 856, ETLA, Helsinki.
7. Hermans, R. and Kulvik, M. (2004), 'Projected Growth Effects of the Biotechnology Industry - the Fourth Pillar of the Economy', ETLA Discussion Paper No. 894, ETLA, Helsinki.
8. Hermans, R. and Ylä-Anttila, P. (2004), 'The biotechnology sector and the future of the Finnish industry', in Luukkonen, T., Ed., 'Biotechnology in Finland: The Promotion of Knowledge-based Business', Series B, no. 207, ETLA, Helsinki (In Finnish with English summary).
9. Nilsson, A. S. (2001), 'Biotechnology firms in Sweden', Small Business Economics, No. 17, pp. 91-103.
10. Hermans, R. and Luukkonen, T. (2002), 'Findings of the ETLA Survey on Finnish Biotechnology Firms', ETLA Discussion Paper No. 819, ETLA, Helsinki.
11. Lemola, T. (2002), 'Convergence of national science and technology policies: The case of Finland', Research Policy, Vol. 31, pp. 1481-1490.
12. Georghiou, L., Smith, K., Toivanen, O. and Ylä-Anttila, P. (2003), 'Evaluation of the Finnish Innovation Support System', Publication 5/2003, Ministry of Trade and Industry, Helsinki.
13. Ylä-Anttila, P. and Lemola, T. (2003), 'Transformation of Innovation System in a Small Country - the Case of Finland', paper presented in the First Globelics Conference, Rio de Janeiro, 2nd - 6th November, 2003.
14. Rouvinen, P. and Ylä-Anttila, P. (2003), 'Little Finland's transformation to a Wireless Giant', in Dutta, S., Lanvin B. and Paua, F., Eds, 'The Global Information Technology Report - Towards an Equitable Information Society', Oxford University Press/World Economic Forum, New York/Oxford.
15. Ali-Yrkkö, J. and Hermans, R. (2004), 'Nokia - a giant in the Finnish innovation system', in Scienstock, G., Ed., 'Embracing the Knowledge Economy', Edward Elgar Publishing.
16. Kafatos, F. C., Beyreuther, K., Chua, N., Mach, B., Owen, D. and Steitz, J. (2002) 'Biotechnology in Finland - Impact of Public Funding and Strategies for the Future Evaluation Report', Publications of the Academy of Finland, no. 11/02.
17. Luukkonen, T. and Palmberg, C. (2004), 'The commercialisation of knowledge: Differences between the Finnish biotechnology and ICT sectors', in Carayannis, E. G., Campbell, D. F. J. and Liyanage, S., Eds, 'Knowledge Creation, Diffusion and Use in Innovative Networks & Clusters: A Comparative Systems Approach Across the U.S., Europe and Asia Technology', Innovation and Knowledge Management Book Series, Greenwood Publishing Group, Greenwood, Westport, CT (forthcoming).
18. Hermans, R. and Kulvik, M. (2004), 'The Health care cost crisis and the growth potential of the biotechnology industry', Finnish Econ. Soc., no. 2/2004, pp. 103-108.
19. Krueger, A. and Tuncer, P. (1982), 'A empirical test of the infant industry argument', Amer. Econ. Rev., Vol. 72(5) pp. 1142-1152.
20. Symposium on Infant Industries (2003), Oxford Development Studies, Vol. 31(1) pp. 3-20.
21. Hermans, R. and Kulvik, M. (2004), 'Measuring intellectual capital and sources of equity financing - value platform perspective within the Finnish bio-pharmaceutical industry', Int. J. Learning Intellectual Capital (forthcoming).
22. Tahvanainen, A.-J. (2004), 'Growth inhibitors of entrepreneurial academic spin-offs: The case of Finnish biotechnology', Int. J. Innovation Technol. Manage. (forthcoming).
23. Kaste, M. (2004), 'The budget or the patient? Accurate and well-timed treatment in the most advantageous choice for society', Duodecim Med. J., Vol. 120(9), pp. 1053-1055 (in Finnish).
24. Hankey, G. J. and Warlow, C. P. (1999), 'Treatment and secondary prevention of stroke: Evidence, costs, and effects on individuals and populations', The Lancet, Vol. 354, pp. 1457-1463.
25. Warlow, C., Sudlow, C., Dennis, M., Wardlaw, J. and Sandercock, P. (2003), 'Stroke', The Lancet, Vol. 362, pp. 1211-1224.
26. Kaste, M., Fogelholm, R. and Rissanen, A. (1998), 'Economic burden of stroke and evaluation of new therapies', Public Health, Vol. 112, pp. 103-112.
27. Fogelholm, R., Rissanen, A. and Nenonen, M. (2001), 'Direct and indirect costs induced by ischaemic stroke in Finland', Finnish Med. J., Vol. 56(36), pp. 3563-3567 (in Finnish).
28. Lindsberg, P. J., Roine, R. O. and Kaste, M. (2000), 'Thrombolysis in the treatment of acute ischaemic stroke. What are the likely pharmacoeconomic consequences?', CNS Drugs, vol., 14, pp. 1-9.